—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...

Integrating plasma next-generation sequencing (NGS) alongside tissue testing when determining lung cancer diagnosis may improve outcomes for patients. Carrying out plasma next-generation sequencing ...

Please provide your email address to receive an email when new articles are posted on . National Comprehensive Cancer Network guidelines recommend all patients with advanced nonsquamous non-small cell ...

The US Food and Drug Administration (FDA) has granted approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a treatment for non-small cell lung cancer (NSCLC). The test serves as a ...

Please provide your email address to receive an email when new articles are posted on . NCCN recommends osimertinib plus chemotherapy or lazertinib plus amivantamab-vmjw as first-line options for EGFR ...

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers. Joshua Sabari, MD: I recommend testing up front. All patients with ...

Charu Aggarwal, M.D., MPH: Recent data show that there are many challenges. We saw presentations at this year’s American Society of Clinical Oncology annual meeting where rates of molecular testing ...

The evidence is increasingly clear: comprehensive biomarker testing can improve patient outcomes and may reduce overall cost of care. So why is knowing a patient’s biomarker so important to better ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...